Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma

Fig. 2

General overview of the course of the trial. The trial consists of four phases: Screening, aiming at verification of patients’ eligibility for the trial; Baseline evaluation, obtaining the basic information about the disease before treatment; Treatment, in which the combination therapy is administered and the response evaluation and toxicities are investigated; Follow-up, observing the long-term safety and clinical efficacy of this strategy. Abbreviations: PDAC, pancreatic ductal adenocarcinoma

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us